Cannabis terapéutico y COVID-19: entre el oportunismo y la infoxicación

Autores/as

  • Francisco Pascual Pastor Presidente Socidrogalcohol. Asesor de CAARFE. Investigador Grupo Prevengo UMH. Coordinador UCA-Alcoi. Grupo Ibero Ciência.
  • Manuel Isorna Folgar Universidad de Vigo. Grupo PS1. Ayuntamiento de Catoira. Grupo EVICT. Grupo Ibero Ciência.
  • Nelson Carvalho Unidade Operacional de Intervenção em Comportamentos Aditivos e Dependências - IASAÚDE - IP-RAM. Grupo Ibero Ciência
  • Félix Carvalho UCIBIO, REQUIMTE, Laboratório de Toxicología, Faculdade de Farmácia da Universidade do Porto. Portugal. Grupo Ibero Ciência
  • Francisco Arias Horcajadas Programa de Alcohol y Patología Dual. Hospital Doce de Octubre, Madrid. Grupo Ibero Ciência

DOI:

https://doi.org/10.20882/adicciones.1603

Palabras clave:

Cannabis, COVID-19.

Resumen

Editorial.

Citas

Agoritsas, T., Boroli, F., Calmy, A., Gartner, B., Gayetageron, A., Guessous, I.,… Zanella, M. (Groupe Guidelines COVID). (2020). Cannabinoïdes et COVID-19: évaluation pharmacologique. Hospitaux Universitaires Genève. Département de Médicine Aigüe. Service de Pharmacologie et Toxicologie Cliniques. Recuperado de https://www.hug-ge.ch/sites/interhug/files/structures/coronavirus/documents/cannabinoides_et_covid-19.pdf.

Blachman-Braun, R., Del Mazo-Rodríguez, R. L., López-Sámano, G. y Buendía-Roldán, I. (2014). Hookah, is it really harmless? Respiratory Medicine, 108, 661-667. doi:10.1016/j.rmed.2014.01.013.

Brown, J. D. (2020). Cannabidiol as prophylaxis for SARS-CoV-2 and COVID-19? Unfounded claims versus potential risks of medications during the pandemic. Research in Social & Administrative Pharmacy. Avance de publicación on-line. doi:10.1016 / j.sapharm.2020.03.020.

Confac (2020). Nacida de la necesidad: se publica guía de buenas prácticas para el desconfinamiento de las asociaciones cannábicas. Recuperado de: https://confac.org/.

Dunlop, A., Lokuge, B., Masters, D., Sequeira, M., Saul, P., Dunlop, G., Ryan, J., Hall, M. y Maher, L. (2020). Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic. Harm Reduction Journal, 17, 26. doi:10.1186/s12954-020-00370-7.

Etemadi, A., Gandomkar, A., Freedman, N. D., Moghadami, M., Fattahi, M. R., Poustchi, H.,... Malekzadeh, R. (2017). The association between waterpipe smoking and gastroesophageal reflux disease. International Journal of Epidemiology, 46, 1968-1977. doi:10.1093/ije/dyx158.

Filbey, F. M., McQueeny, T., DeWitt, S. J. y Mishra, V. (2015). Preliminary findings demonstrating latent effects of early adolescent marijuana use onset on cortical archi-tecture. Developmental Cognitive Neuroscience, 16, 16-22. doi:10.1016/j.dcn.2015.10.001.

Galindo, C., González, A., Espigares, E. y Moreno, E. (2019). Riesgo para la salud pública de fumar tabaco en cachimba. Higiene y Sanidad Ambiental, 19, 1775-1785.

García, F. (9 de mayo de 2020). La marihuana como servicio esencial. La Vanguardia, pp.43.

García Álvarez, L., Gomar, J. J., García-Portilla, M. P. y Bobes, J. (2019). Cannabis use and cognitive impairment in schizophrenia and first-episode psychosis. Adicciones, 31, 89–94. doi:10.20882/adicciones.1328.

García-Álvarez, L., de la Fuente-Tomás, L., Sáiz, P. A., García-Portilla, M. P. y Bobes, J. (2020). Will changes in alcohol and tobacco use be seen during the COVID-19 lockdown?. Adicciones, 32, 85-89. doi:10.20882/adicciones.1546.

Hall, W., Degenhardt, L. y Teesson, M. (2009). Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base. Addictive Behaviors, 34, 795-799. doi:10.1016/j.addbeh.2009.03.040.

Isorna, M., Vázquez, M. J., Redondo, L. y Veiga, S. (2019). Cómo pueden las fake news o falsas creencias contribuir al consumo de cannabis. En M. Isorna y A. Rial (Coord.) El consumo de cannabis y sus derivados: Mitos, posverdades y desafíos (pp. 161-175). Madrid: Dykinson.

Israel inicia pruebas clínicas para tratar el COVID-19 con cannabis (s.f.). Recuperdo de https://canamo.net/noticias/mundo/israel-inicia-pruebas-clinicas-para-tratar-el-covid-19-con-cannabis.

McCoy, K. L. (2016). Interaction between cannabinoid system and toll-like receptors controls inflammation. Mediators of Inflammation, ID 5831315. doi:10.1155/2016/5831315.

Mons, U., Müezzinler, A., Gellert, C., Schöttker, B., Abnet, C. C., Bobak, M., de Groot, L., … CHANCES Consortium (2015). Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. The British Medical Journal, 350, h1551. doi:10.1136/bmj.h1551.

National Academies of Sciences, Engineering and Medicine. [NASEM]. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press. doi:10.17226/24625.

Owen, K. P., Sutter, M. E. y Albertson, T. E. (2014). Marijuana: respiratory tract effects. Clinical Reviews in Allergy & Immunology, 46, 65–81. doi:10.1007/s12016-013-8374-y.

Rial, A., Burkhart, G., Isorna, M., Barreiro, C., Varela, J. y Golpe, S. (2018). Cannabis use among adolescents: risk pattern, implications and possible explanatory variables. Adicciones, 31, 64-77. doi:10.20882/adicciones.1212.

Satre, D. D., Hirschtritt, M. E., Silverberg, M. J. y Sterling, S. A. (2020). Addressing problems with alcohol and other substances among older adults during the COVID-19 pandemic. The American Journal of Geriatric Psychiatry, S1064-7481(20)30296-7. Avance de publicación on-line. doi:10.1016/j.jagp.2020.04.012.

Schulte, M. T. y Hser, Y. (2013). Substance use and associated health conditions throughout the lifespan. Public Health Reviews, 35, 3. doi:10.1007/BF03391702.

Sexton, M. (2020). Cannabis in the time of coronavirus disease 2019: The yin and yang of the endocannabinoid system in immunocompetence. The Journal of Alternative and Complementary Medicine, 10, 1-5. doi:10.1089/acm.2020.0144.

Sexton, M., Cudaback, E., Abdullah R., Finnell, J., Mischley, L., Rozga, M.,… Stella, N. (2014). Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Inflammopharmacology, 22, 295-303. doi: 10.1007/s10787-014-0214-z.

Sexton, M., Shelton, K., Haley P. y West, M. (2018). Evaluation of cannabinoid and terpenoid content: cannabis flower compared to supercritical CO2 concentrate. Planta Medica, 84, 234-241. doi:10.1055/s-0043-119361.

Tashkin, D. P. (2013). Effects of marijuana smoking on the lung. Annals of the American Thoracic Society, 10, 239-247. doi:10.1513/AnnalsATS.201212-127FR.

Tetrault, J. M., Crothers, K., Moore, B. A., Mehra, R., Concato, J. y Fiellin, D. A. (2007). Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Archives of Internal Medicine, 167, 221-228. doi:10.1001/archinte.167.3.221.

Volkow, N. (2020). Collision of the COVID-19 and Addiction Epidemics. Annals of Internal Medicine. Avance de publicación on-line. doi:10.7326/M20-1212

Wang, B., Kovalchuk, A., Li, D., Ilnytskyy, Y., Kovalchuk, I. y Kovalchuk, O. (2020). In search of preventative strategies: novel anti-inflammatory high-CBD cannabis sativa extracts modulate ACE2 expression in COVID-19 gateway tissues. Preprints, 2020040315. doi:10.20944/preprints202004.0315.v1.

Wu, L., Ghitza, U., Zhu, H., Spratt, S., Swartz, M. y Mannelli, P. (2018). Substance use disorders and medical comorbidities among high-need, high-risk patients with diabetes. Drug and Alcohol Dependence, 186, 86-93. doi:10.1016/j.drugalcdep.2018.01.008.

Wu, Z. y McGoogan, J.M. (2020). Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA, 323, 1239-1242. doi:10.1001/jama.2020.2648.

Yafai, S. y Etengoff, S. (2020). The case for cannabis. Advising cannabis users about COVID-19. Emergency Medicine News, 42, 5B. doi:10.1097/01.EEM.0000668076.42644.69.

Publicado

2020-07-01

Número

Sección

Editorial